Importantly, dependency on MCL-1 in cancer cells may be exploited for therapeutic gain, and novel agents that specifically target MCL-1 are already undergoing clinical investigation as potential chemotherapeutics in acute myeloid leukemia (AML) and multiple myeloma (MM). This evidence concerns the gene MCL1 and cancer.